← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › ANABOLIC AGENTS FOR SYSTEMIC USE › ANABOLIC STEROIDS › Androstan derivatives
androstanolone
A14AA01
Forms & Strengths
- Transdermal gel: 25 mg/2.5 g (1%)
- Topical solution: 20 mg/mL
- Implant pellets: 100 mg, 200 mg
Adult Dosing
- Hypogonadism (transdermal gel): 50 mg applied topically to clean, dry, intact skin of the shoulders, upper arms, or abdomen once daily
- Hypogonadism (topical solution): 60 mg (3 pump actuations) applied once daily to the axillae
- Androgen deficiency (implant): 100-600 mg subcutaneously every 3-6 months depending on clinical response
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
- Not indicated for use in children or adolescents due to the risk of premature epiphyseal closure and virilization
Indications
- Replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism)
Mechanism of Action
- Synthetic derivative of testosterone (also known as stanolone or 5alpha-dihydrotestosterone)
- Binds to intracellular androgen receptors in target tissues, mediating anabolic effects (protein synthesis, nitrogen retention) and androgenic effects (secondary sexual characteristics)
Contraindications
- Known or suspected carcinoma of the breast or the prostate
- Hypersensitivity to androstanolone or any excipients in the formulation
- Pregnancy and lactation
- Men with severe hepatic, renal, or cardiac disease
Adverse Reactions
- Application site reactions (erythema, pruritus, irritation)
- Acne, alopecia, hirsutism, oily skin
- Gynecomastia, breast tenderness
- Prostatic hypertrophy, elevated prostate-specific antigen (PSA)
- Polycythemia (elevated hematocrit/hemoglobin)
- Edema, weight gain, hypertension
- Hepatic dysfunction, lipid profile alterations
Drug Interactions
- Oral anticoagulants: May enhance the anticoagulant effect; monitor INR closely
- Corticosteroids: Concurrent administration may increase the risk of edema
- Insulin and antidiabetic agents: Androgens may decrease blood glucose and insulin requirements
- Oxyphenbutazone: May elevate plasma levels of oxyphenbutazone
Curated Content: Needs Vetting Before Put to Clinical Use